Repare Therapeutics Statistics
Share Statistics
Repare Therapeutics has 42.51M shares outstanding. The number of shares has increased by 0.75% in one year.
| Shares Outstanding | 42.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 28.79M |
| Failed to Deliver (FTD) Shares | 535 |
| FTD / Avg. Volume | 0.32% |
Short Selling Information
The latest short interest is 749.74K, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 749.74K |
| Short % of Shares Out | 1.76% |
| Short % of Float | 2.61% |
| Short Ratio (days to cover) | 6.38 |
Valuation Ratios
The PE ratio is -3.28 and the forward PE ratio is -1.19.
| PE Ratio | -3.28 |
| Forward PE | -1.19 |
| PS Ratio | 6.01 |
| Forward PS | 6.9 |
| PB Ratio | 1.45 |
| P/FCF Ratio | -2.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Repare Therapeutics Inc. has an Enterprise Value (EV) of 199.42M.
| EV / Earnings | -2.13 |
| EV / Sales | 3.9 |
| EV / EBITDA | -1.75 |
| EV / EBIT | -1.72 |
| EV / FCF | -1.54 |
Financial Position
The company has a current ratio of 6.24, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.24 |
| Quick Ratio | 6.24 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.58 |
| Cash Flow / Debt | -37.29 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.44% and return on capital (ROIC) is -49.03%.
| Return on Equity (ROE) | -0.44% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -49.03% |
| Revenue Per Employee | 285.66K |
| Profits Per Employee | -524.00K |
| Employee Count | 179 |
| Asset Turnover | 0.2 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -9.38M |
| Effective Tax Rate | 0.09 |
Stock Price Statistics
The stock price has increased by -73.93% in the last 52 weeks. The beta is 0.71, so Repare Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -73.93% |
| 50-Day Moving Average | 3.31 |
| 200-Day Moving Average | 3.6 |
| Relative Strength Index (RSI) | 33.08 |
| Average Volume (20 Days) | 165.42K |
Income Statement
In the last 12 months, Repare Therapeutics had revenue of $51.13M and earned -$93.80M in profits. Earnings per share was $-2.23.
| Revenue | 51.13M |
| Gross Profit | -80.07M |
| Operating Income | -116.22M |
| Net Income | -93.80M |
| EBITDA | -114.27M |
| EBIT | -116.22M |
| Earnings Per Share (EPS) | -2.23 |
Balance Sheet
The company has $111.27M in cash and $3.41M in debt, giving a net cash position of $107.86M.
| Cash & Cash Equivalents | 111.27M |
| Total Debt | 3.41M |
| Net Cash | 107.86M |
| Retained Earnings | -333.11M |
| Total Assets | 206.39M |
| Working Capital | 169.32M |
Cash Flow
In the last 12 months, operating cash flow was -$127.16M and capital expenditures -$1.94M, giving a free cash flow of -$129.10M.
| Operating Cash Flow | -127.16M |
| Capital Expenditures | -1.94M |
| Free Cash Flow | -129.10M |
| FCF Per Share | -3.07 |
Margins
Gross margin is -156.59%, with operating and profit margins of -227.3% and -183.44%.
| Gross Margin | -156.59% |
| Operating Margin | -227.3% |
| Pretax Margin | -201.79% |
| Profit Margin | -183.44% |
| EBITDA Margin | -223.48% |
| EBIT Margin | -227.3% |
| FCF Margin | -252.47% |
Dividends & Yields
RPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -126.7% |
| FCF Yield | -172.06% |
Analyst Forecast
The average price target for RPTX is $7, which is 297.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 297.7% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.38 |
| Piotroski F-Score | 4 |